Miravo Healthcare
http://www.miravohealthcare.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Miravo Healthcare
Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Biotech entrepreneurs tend to be an optimistic group, and there were many pockets of hope for 2024. However, the consensus remains that depressed valuations and paucity of fresh funds will continue to pose a challenge for the sector, and companies will need to prioritize carefully and work even harder to demonstrate and create value.
BioNTech Banks On Oncology Pipeline As COVID Cash Dries Up
Like rival Moderna, company reported a steep drop in revenue, but it is still prioritizing its COVID-19 vaccine as an investment priority, while also moving ahead with multiple deals with China-based firms.
Can BioNTech Take China Early-Stage Biotech Innovation Global?
BioNTech is betting on China's innovative capabilities by inking multiple deals with local startups to expand its pipeline beyond mRNA vaccines.
BioNTech Looks For Faster Entry Into Cancer Therapies As COVID-19 Recedes
BioNTech continues to earn big money from its COVID-19 vaccine, but wants to become an on-market cancer company sooner rather than later.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- OTC, Consumer
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
- Transdermal
- Other Names / Subsidiaries
-
- Dimethaid Research
- Nuvo Ireland
- Nuvo Research, Inc.
- Nuvo Pharmaceuticals, Inc.
- Oxo Chemie GmbH
- Tribute Pharmaceuticals Canada Inc.
- ZARS Pharma, Inc.,
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice